These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6073365)

  • 1. The "Long" amendment.
    Provost GP
    Am J Hosp Pharm; 1967 Dec; 24(12):665. PubMed ID: 6073365
    [No Abstract]   [Full Text] [Related]  

  • 2. Any willing provider meets the formulary.
    Barrueta A
    Health Syst Rev; 1995; 28(4):20, 22-3. PubMed ID: 10144359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enterprise liability for bad outcomes from drug therapy: the doctor, the hospital, the pharmacy, and the drug firm.
    Furrow BR
    Spec Law Dig Health Care Law; 1998 Apr; (229):9-69. PubMed ID: 10178162
    [No Abstract]   [Full Text] [Related]  

  • 4. Standing on your own feet.
    Apple WS
    J Am Pharm Assoc; 1974 Jun; 14(6):278-80. PubMed ID: 4840422
    [No Abstract]   [Full Text] [Related]  

  • 5. Rx changes disputed. Fla. doc, pharmacist groups argue over proposed rule.
    Robeznieks A
    Mod Healthc; 2005 Sep; 35(37):34. PubMed ID: 16224953
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicine, pharmacy, and industry--a fly's eye view of health care.
    Halperin JA
    Ann Pharmacother; 1995 Sep; 29(9):925-33. PubMed ID: 8547743
    [No Abstract]   [Full Text] [Related]  

  • 7. ASHP guidelines for pharmacists on the activities of vendors' representatives in organized health care systems. American Society of Hospital Pharmacists.
    Meyer GE; Keith TD; Gutfeld MB; Johnson D
    Am J Hosp Pharm; 1994 Feb; 51(4):520-1. PubMed ID: 8017422
    [No Abstract]   [Full Text] [Related]  

  • 8. Address of the outgoing president. The importance of member involvement.
    Denmark GD
    J Am Pharm Assoc; 1974 Sep; 14(9):453-4, 67. PubMed ID: 4420336
    [No Abstract]   [Full Text] [Related]  

  • 9. Bill 102: deal or no deal for big pharma.
    Rasky H
    Health Law Can; 2007 May; 27(4):73-84. PubMed ID: 17580795
    [No Abstract]   [Full Text] [Related]  

  • 10. PMA (Pharmaceutical Manufacturers Association) finances grassroots coalition to fight changes in Medicaid formularies.
    Gatty B
    Hosp Formul; 1993 Aug; 28(8):714, 713. PubMed ID: 10127749
    [No Abstract]   [Full Text] [Related]  

  • 11. American Pharmaceutical Association House of Delegates, May 13-18, 1978, Montreal, Quebec, Canada. Report of the Policy Committee on Organizational Affairs.
    Am Pharm; 1978 Jul; 18(8 Spec No):32-5. PubMed ID: 665505
    [No Abstract]   [Full Text] [Related]  

  • 12. American Pharmaceutical Association House of Delegates, May 13-18 1978, Montreal, Quebec, Canada. Report of the Policy Committe on Public Affairs.
    Am Pharm; 1978 Jul; 18(8 Spec No):22-9. PubMed ID: 665504
    [No Abstract]   [Full Text] [Related]  

  • 13. The mail order pharmacy case: APhA's major antitrust victory.
    Jawaid A
    Am Pharm; 1981 Oct; NS21(10):54-7. PubMed ID: 7340495
    [No Abstract]   [Full Text] [Related]  

  • 14. The economic wisdom of regulating pharmaceutical "freebies".
    Fisher SH
    Duke Law J; 1991 Feb; (1):206-39. PubMed ID: 10114416
    [No Abstract]   [Full Text] [Related]  

  • 15. The P&T Society.
    Bootman L
    Manag Care Interface; 2006 Feb; 19(2):13, 15. PubMed ID: 16583504
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: USP-NF consolidation.
    Tice LF
    Am J Pharm Sci Support Public Health; 1974; 146(4):99-100. PubMed ID: 4423145
    [No Abstract]   [Full Text] [Related]  

  • 17. The future of managed care drug formularies.
    Navarro RP
    Med Interface; 1994 Apr; 7(4):62-4. PubMed ID: 10133359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic program for drug quality.
    Feldmann EG
    J Am Pharm Assoc; 1967 Jun; 7(6):301-2. PubMed ID: 6045621
    [No Abstract]   [Full Text] [Related]  

  • 19. Product selection: community formularies and legal aspects. The pharmacist's responsibility in product selection.
    Kanig JL
    Am J Pharm Sci Support Public Health; 1972; 144(5):133-8. PubMed ID: 4641165
    [No Abstract]   [Full Text] [Related]  

  • 20. Report of the Committee on Anti-Substitution Policy.
    Am J Pharm Sci Support Public Health; 1971; 143(6):195-200. PubMed ID: 5140168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.